Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Champions Oncology's share price for the quarter that ended in Jan. 2024 was $5.81. Champions Oncology's Shares Outstanding (EOP) for the quarter that ended in Jan. 2024 was 13.59 Mil. Therefore, Champions Oncology's market cap for the quarter that ended in Jan. 2024 was $78.98 Mil.
Champions Oncology's quarterly market cap
declined
from Jul. 2023 ($87.65 Mil) to Oct. 2023 ($74.22 Mil) but then
increased
from Oct. 2023 ($74.22 Mil) to Jan. 2024 ($78.98 Mil).
Champions Oncology's annual market cap
declined
from Apr. 2021 ($143.93 Mil) to Apr. 2022 ($103.85 Mil) and
declined
from Apr. 2022 ($103.85 Mil) to Apr. 2023 ($66.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Champions Oncology's Enterprise Value for Today is $66.01 Mil.
Champions Oncology Market Cap Historical Data
The historical data trend for Champions Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's Market Cap
For the Biotechnology subindustry, Champions Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Market Cap falls into.
Champions Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Champions Oncology's Market Cap for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Champions Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Champions Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology (Champions Oncology) Business Description
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 